Maher Khaled, who managed intellectual property arising from medical research at University of Queensland, has joined Preveceutical Medical as director of international operations.

Maher Khaled (pictured), a director at University of Queensland’s tech transfer office UniQuest, was appointed director of international operations at preventative health sciences company Preveceutical Medical on Monday.

Khaled became director of commercial engagement, personalised medicine at UniQuest in February 2014, and was responsible for commercialising technologies related to personalised medicine, diagnostics and genomics through licensing, spinouts and collaborative development.

His curriculum also includes six years as an investment manager with Cambridge Enterprise Seed Funds, the seed-stage vehicle of University of Cambridge’s tech transfer arm Cambridge Enterprise. He held that position from May 2005 to August 2011.

At Preveceutical, he will oversee the company’s development of therapeutic technology and manage the company’s operations in Australia. He will lead commercialisation efforts, engage with industry and review acquisition and licensing opportunities.

He will work closely with Harry Parekh, chief research officer at Preveceutical.

UniQuest and Prevecutical Medical previously inked a research collaboration agreement in 2017 to develop non-addictive analgesics for the treatment of pain, in an effort to find an alternative to addictive opioids.

Khaled said: “I am excited by the partnership opportunities offered by the commercial ventures Preveceutical both has and is planning.  

“I look forward to pursuing these partnerships internationally whilst working closely with Dr Parekh to advance the therapeutic research programs he is leading at the University of Queensland.”

– Image courtesy of UniQuest